Since sST2 neutralizes the effect of IL-33, it is considered an anti-inflammatory factor in conditions in which IL-33 takes place in the driving inflammatory processes, such as asthma and Pso, and IL-33 neutralization may represent a novel therapeutic approach in these diseases. This evidence concerns the gene IL33 and asthma.